摘要
为了探讨促红细胞生成素(EPO)治疗慢性肾衰患者对铁调素、纤维蛋白原降解产物(FDP)及红细胞免疫水平的影响。选取我院2014年1月至2016年1月间收治的30例规律使用EPO治疗的肾功能不全肾衰期患者作为研究对象进行自身对照研究,患者使用EPO治疗12周,分别于治疗前、治疗后检测并比较血清铁调素、FDP、红细胞免疫水平等指标。研究显示,相较于治疗前,30例患者接受治疗后血清中的RBC、Hb、TRF、PA、血清铁和RBC-C3b RR比例均发生显著性提高,差异具有统计学意义(p<0.05);而hs-CRP、FDP、铁调素水平以及RBC-ICR比例发生显著性降低,差异具有统计学意义(p<0.05);但血清中Scr水平无明显变化,差异不具有统计学意义(p>0.05)。因此,EPO治疗慢性肾衰患者能通过调节血清铁调素水平纠正肾性贫血,同时改善患者的红细胞免疫功能及营养状态。
T he aim of study was to investigate the effects of erythropoietin （EPO） on fructurin, fibronectin degradation products （FDP） and erythrocyte immunity on patients with chronic renal failure. We selected 30 patients with renal dysfunction treated with EPO in our hospital from January 2014 to January 2016 as our subjects. The patients were treated with EPO for 12 weeks. Serum ferrucine, FDP and erythrocyte immune level were detected and comparedbefore and after treatment. The result showed that after treatment, the levels ofRBC, Hb, TRF, PA, serum iron and RBC-C3bRRin 30 patients were significantly higher than those before treatment, and the difference was statistically significant （p〈0.05）. While the levels ofhs-CRP, FDP, hepcidin, and RBC-ICR were significantly lower than those before treatment, and the difference was statistically significant （p〈0.05）. Meanwhile, Scr in serum did not change, and the difference had no statistical significance （/9〉0.05）. Thus, EPO treatment on patients with chronic renal failure could regulate serum levels of iron fractions to correct renal anemia, and improve the patient＇s immune function of red blood cell and nutritional status.
作者
陈丽平
Chen Liping(Medical College of Xuchang University, Xuchang, 461000)
出处
《基因组学与应用生物学》
CAS
CSCD
北大核心
2017年第11期4516-4522,共7页
Genomics and Applied Biology
基金
许昌学院医学院资助
